摘要
Sugammadex問世至今已逾10年，已大幅影響許多麻醉醫師選擇神經肌肉阻斷劑的習慣和考量；有別於傳統拮抗神經肌肉阻斷劑的藥物，乙醯膽鹼酯酶抑制劑（acetylcholinesterase inhibitors），sugammadex具有專一、快速及可信賴的拮抗效果，即使病人處在深度的神經肌肉阻斷狀態，也可透過sugammadex被逆轉。只要依循在不同的神經阻斷狀態給予相對應的建議劑量，用藥後幾乎不會出現神經肌肉阻斷劑在體內殘留的情形。本篇文章將介紹sugammadex的作用機轉、適應症、不良反應等，並整理最新的研究報告讓臨床醫師們對這個藥物有更多認識。
參考文獻
Fortier LP, McKeen D, Turner K, et al. The RECITE study: a Canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade. Anesth Analg 2015;121:366-72.
Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008;107:130-7.
Butterly A, Bittner EA, George E, et, al. Postoperative residual curarization from intermediate-acting neuromuscular blocking agents delays recovery room discharge. Br J Anaesth 2010;105:304-9.
Nag K, Singh DR, Shetti AN, et al. Sugammadex: a revolutionary drug in neuromuscular pharmacology. Anesth Essays Res 2013;7:302-6.
Carron M, Baratto F, Zarantonello F, et al. Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center. Clinicoecon Outcomes Res 2016;8:43-52.